Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40.
- SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services Task Force (USPSTF) recommending that women begin breast cancer screening starting at age 40.
- Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
- The change to the recommended age comes in response to rising breast cancer rates among younger women and racial disparities in breast cancer diagnosis and mortality.
- Atossa Therapeutics recognizes the significance of these improved guidelines in empowering both healthcare providers and patients to make informed decisions regarding breast cancer screening and treatment.